Results 221 to 230 of about 2,115,183 (392)
Sustained‐release valproate in partial epilepsy: comparison between VIPe and Gulf VIPe study findings [PDF]
Dirk Deleu +4 more
openalex +1 more source
Pro‐Inflammatory c‐Met+ CD4 T Cells in Multiple Sclerosis
Objective Hepatocyte growth factor (HGF) binds exclusively the c‐Met surface receptor, and the HGF/c‐Met axis regulates T cell function in autoimmune diseases. We analyzed c‐Met expression on human CD4 T cells in the blood and cerebrospinal fluid (CSF) from patients with multiple sclerosis (MS) versus non‐inflammatory neurological disease (NIND), to ...
Gautier Breville +6 more
wiley +1 more source
Back Again to the Future: A New Era for Cerebroprotection
Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. In the future, successful cerebroprotection will involve targeting all elements of the neurovascular unit. Preclinical trials must include functional outcomes, as well as lesion morphometry.
Patrick Lyden
wiley +1 more source
New Insights into the Clinical Management of Partial Epilepsies [PDF]
Édouard Hirsch +2 more
openalex +1 more source
Objectives Multiple sclerosis (MS) onset risk factors include Epstein–Barr virus (EBV) indices (including host response), lower serum 25‐vitamin D (25(OH)D) levels, low sun exposure, and HLA‐DRB1*1501. The underlying molecular mechanisms are unclear. Here, we examined mediation through differential DNA methylation (DNAm) to better understand possible ...
Steve Simpson‐Yap +37 more
wiley +1 more source
Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base [PDF]
Christian Brandt +2 more
openalex +1 more source

